Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks

Several exemptions exist among President Donald Trump‘s broad tariffs, which were announced on Wednesday.

The biopharma industry has historically been shielded from tariffs, including during Trump’s first term. Given its significant manufacturing presence in Europe, investors had feared global tariffs could disrupt the sector.

Morningstar reports that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the industry $20 billion, with some of the largest firms facing annual tariffs of up to $1 billion.

Also Read: French President Macron Suggests Suspension Of EU Investments In US Amid Tariff Turmoil, Vows ‘More Powerful’ Response

Goldman Sachs expects continued volatility in the biotechnology sector (XBI and S&P 500 are down about 14% and 7% year-to-date, respectively), driven by broader economic uncertainty and unclear healthcare policy.

Analyst Salveen Richter has analyzed ...